School of Medicine, Huzhou University; Huzhou Central Hospital, Huzhou, China
The First Affiliated Hospital of Huzhou University, Huzhou University, Huzhou, China.
BMJ Open. 2021 Mar 9;11(3):e043807. doi: 10.1136/bmjopen-2020-043807.
Efficacy of aliskiren combination therapy with other antihypertensive has been evaluated in the treatment of patients with hypertension in recent systematic reviews. However, most previous reviews only focused on one single health outcome or one setting, none of them made a full summary that assessed the impact of aliskiren combination treatment comprehensively. As such, this umbrella review based on systematic reviews and meta-analyses is aimed to synthesise the evidences on efficacy, safety and tolerability of aliskiren-based therapy for hypertension and related comorbid patients.
A comprehensive search of PubMed, EMBASE, Cochrane Library, CNKI published from inception to August 2020 will be conducted. The selected articles are systematic reviews which evaluated efficacy, safety and tolerability of aliskiren combination therapy. Two reviewers will screen eligible articles, extract data and evaluate quality independently. Any disputes will be resolved by discussion or the arbitration of a third person. The quality of reporting evidence will be assessed using the Assessment of Multiple Systematic Reviews V.2 tool tool. We will take a mixed-methods approach to synthesising the review literatures, reporting summary of findings tables and iteratively mapping the results.
Ethical approval is not required for the study, as we would only collect data from available published materials. This umbrella review will be also submitted to a peer-reviewed journal for publication after completion.
CRD42020192131.
最近的系统评价评估了阿利吉仑联合其他降压药治疗高血压患者的疗效。然而，大多数先前的综述仅关注单一的健康结局或单一的研究环境，没有一个综述全面评估了阿利吉仑联合治疗的综合影响。因此，这项基于系统评价和荟萃分析的伞式综述旨在综合评估阿利吉仑为基础的治疗方案在高血压及相关合并症患者中的疗效、安全性和耐受性。
我们将全面检索从建库至 2020 年 8 月发表在 PubMed、EMBASE、Cochrane Library、CNKI 上的文献。纳入评估阿利吉仑联合治疗疗效、安全性和耐受性的系统评价。两名评审员将独立筛选合格文献、提取数据和评估质量。任何争议将通过讨论或第三方仲裁解决。使用评估多个系统评价工具（AMSTAR 2）评估报告证据的质量。我们将采用混合方法综合评价文献，报告结果总结表，并迭代映射结果。
本研究不需要伦理批准，因为我们仅从现有发表的资料中收集数据。研究完成后，该伞式综述也将提交给同行评议期刊发表。
PROSPERO 注册号：CRD42020192131。
